Efficacy and safety of prucalopride in adults and children with chronic constipation

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 3, 2015, Pages 407-416

  Diederen, Kay ^a   Mugie, Suzanne Marian ^a   Benninga, Marc Alexander ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

5 HT4 receptor; Efficacy; Enterokinetic; Pharmacodynamics; Pharmacokinetics; Prokinetic; R093887; R108512; Safety; Serotonin agonist

Indexed keywords

CISAPRIDE; ELOBIXIBAT; LAXATIVE; MACROGOL 3350; METOCLOPRAMIDE; PLACEBO; POTASSIUM; POTASSIUM CHANNEL HERG; PRUCALOPRIDE; SEROTONIN; TEGASEROD; VELUSETRAG; BENZOFURAN DERIVATIVE; SEROTONIN 4 AGONIST;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGING; CHEMICAL STRUCTURE; CHRONIC CONSTIPATION; CONSTIPATION; DEFECATION; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COATING; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FECES; FECES INCONTINENCE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRANSIT; HEART ARRHYTHMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDLINE; META ANALYSIS; NAUSEA; NONHUMAN; OPEN STUDY; PATIENT SATISFACTION; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM CURRENT; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; CHILD; CHRONIC DISEASE; DRUG EFFECTS; PATHOPHYSIOLOGY; PSYCHOLOGY;

ADULT; BENZOFURANS; CHILD; CHRONIC DISEASE; CONSTIPATION; GASTROINTESTINAL MOTILITY; HUMANS; QUALITY OF LIFE; SEROTONIN 5-HT4 RECEPTOR AGONISTS;

EID: 84921450817     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.996547     Document Type: Review

References (92)

1. Higgins PD, Johanson JF. Epidemiology of constipation in north america: a systematic review. Am J Gastroenterol 2004;99(4):750-9
2. Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in europe and oceania: a systematic review. BMC Gastroenterol 2008;8:5
3. Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol 2011;25(1):3-18
4. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96(11):3130-7
5. Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation-a European perspective. Neurogastroenterol Motil 2011;23(8):697-710
6. Solzi GF, Di C. Are constipated children different from constipated adults? Dig Dis 2000;15213:308-15
7. Enck P. Biofeedback training in disordered defecation: a critical review. Dig Dis Sci 1993;38:1953-60
8. Locke GR, Pemberton JH, Phillips SF. AGA technical review on constipation. Gastroenterology 2000;119(6):1766-78
9. Youssef NN, Langseder AL, Verga BJ, et al. Chronic childhood constipation is associated with impaired quality of life: a case-controlled study. J Pediatr Gastroenterol Nutr 2005;41(1):56-60
10. Rantis PC, Vernava AM, Daniel GL, et al. Chronic constipation - is the workup worth the cost? Dis Colon Rectum 1997;40(3):280-6
11. Liem O, Harman J, Benninga M, et al. Health utilization and cost impact of childhood constipation in the united states. J Pediatr 2009;154(2):258-62
12. Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011(25 Suppl B):11B-5B
13. Wald A, Mueller-Lissner S, Kamm MA, et al. Survey of laxative use by adults with self-defined constipation in south america and asia: a comparison of six countries. Aliment Pharmacol Ther 2010;31(2):274-84
14. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25(5):599-608
15. Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with selfdefined constipation. Aliment Pharmacol Ther 2008;28(7):917-30
16. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996;41(8):1636-42
17. Attar A, Lémann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999;44(2):226-30
18. Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000;46(4):522-6
19. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27(8):685-96
20. Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and welltolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 2011;9(7):577-83
21. Tack J, Müller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009;7(5):502-8
22. Prins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000;129(8):1601-8
23. Gheuens J. Safety alerts for human medical products. Propulsid (cisapride) dear healthcare professional letter 2000
24. Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol Hear Circ Physiol 1997;273(5):H2534-8
25. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and FDA regulatory actions. Am J Gastroenterol 2001;96(6):1698-703
26. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20(2):99-112
27. Ganzini L. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153(12):1469
28. Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. Vascul Pharmacol 2013;58(1-2):150-6
29. Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22(1):42-9
30. Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013;22(2):277-84
31. Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - A double-blind study. Aliment Pharmacol Ther 2011;34(1):41-50
32. Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled Phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106(10):1803-12
33. Cash BD, Chey WD. Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther 2005;22(11-12):1047-60
34. Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol 2014; Epub ahead of print
35. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365(6):527-36
36. Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol 2010;3:49-56
37. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35(7):745-67
38. The European Medicines Agency. European public assessment report (EPAR) for Resolor (prucalopride). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001012/human-med-001030.jsp&mid=WC0b01ac058001d124 [Last accessed 16 October 2014]
39. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13(5):465-72
40. Mader R, Kocher T, Haier J, et al. Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur J Gastroenterol Hepatol 2006;18(9):945-50
41. Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the nonclassical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989;340(4):403-10
42. Markstein R, Matsumoto M, Kohler C, et al. Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1999;359(6):454-9
43. Prins NH, Akkermans LM, Lefebvre RA, et al. 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131(5):927-32
44. Leclere PG, Prins NH, Schuurkes JA, et al. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005;17(3):366-75
45. Cellek S, John a K, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006;18(9):853-61
46. Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423(1):71-83
47. Van De Velde VJ, Ausma JJ, Vandeplassche LM. Kinetics and absolute oral bioavailability of prucalopride. Gastroenterology 2010;138(5 Suppl 1):S-230
48. Van de Velde VA, Vandeplassche LM. Pharmacokinetics of prucalorpide (Resolor) in man. Gut 2008;57(Suppl):A282
49. Winter HS, Van De Velde VJ, Ausma JJ, et al. A single-dose pharmacokinetic trial of prucalopride solution in pediatric subjects with functional fecal retention. Gastroenterology 2009;136(Suppi 1):A510
50. Van De Velde VJ, Ausma JJ, Vandeplassche LM. Food does not affect the oral bioavailability of prucalopride. Gastroenterology 2009;136:A536
51. Van De Velde VJ, Ausma JJ, Vandeplassche LM. Comparative pharmacokinetics of prucalopride in healthy young and elderly subjects. Gastroenterology 2010;138(5 Suppl):S-230
52. Smith WB, Mannaert E, Verhaeghe T, et al. Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study. Drug Des Devel 2012;6:407-15
53. LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum. Neurogastroenterol Motil 2004;16(3):355-64
54. Prins NH, Van Haselen JF, Lefebvre RA, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999;127(6):1431-7
55. Qi H, Luo J, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J Gastroenterol 2003;9(9):2065-7
56. De Winter BY, Boeckxstaens GE, De Man JG, et al. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 1999;45(5):713-18
57. Prins NH, van Der Grijn A, Lefebvre RA, et al. 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132(8):1941-7
58. Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 2002;135(1):135-42
59. Prins NH, Van Der Grijn A, Lefebvre RA, et al. 5-HT 4 receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132(8):1941-7
60. Briejer MR, Meulemans AL, Wellens A, et al. R093877 dose-dependently accelerates gastric emptying in conscious dogs. Gastroenterology 1997;112:A705
61. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44(5):682-6
62. Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13(11):1493-7
63. Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42(4):511-16
64. De Schryver AM, Andriesse GI, Samsom M, et al. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002;16(3):603-12
65. Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55(10):2912-21
66. Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16(7):1347-56
67. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
68. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16(4):759-67
69. Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Digestion 2003;67(1-2):82-9
70. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358(22):2344-54
71. Tack J, Outryve MV, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2008;58(3):357-65
72. Quigley EM, Vandeplassche L, Kerstens RA. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebocontrolled study. Aliment Pharmacol Ther 2009;29(3):315-28
73. Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2014;26(1):21-7
74. Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32(9):1113-23
75. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the asiapacific region: a randomized, doubleblind, placebo-controlled study. Neurogastroenterol Motil 2012;24(11):999-e541
76. Emmanuel A, Cools M, Vandeplassche L, et al. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol 2014;109(6):887-94
77. Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39(3):239-53
78. Cinca R, Chera D, Gruss HJ, et al. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment. Aliment. Pharmacol 2013;37(9):876-86
79. Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr 2013;57(2):197-203
80. Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no More Effective than Placebo for Children with Functional Constipation. Gastroenterology 2014;147(6):1285-95
81. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21(12):1256-e117 .. Phase-II study evaluating the effect and cardiovasculair safety in an elderly population with history of stable cardiovascular disease.
82. Van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006;101(10):2401-9
83. Gatandiuk S, Beyens G, Ausma J, et al. Evaluation of the efficacy safety and tolerability of prucalopride (Resolor (R)) given subcutaneously in patients undergoing elective partial colectomies. Gastroenterology 2008;134:A138
84. Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction-a double-blind, placebo-controlled, crossover, multiple n = 1 study. Aliment Pharmacol Ther 2012;35(1):48-55
85. Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37(4):431-6
86. D'Hooghe B, Guillaum D MR, et al. Treatment of constipation in multiple sclerosis patients: pilot study with the novel enterokinetic prucalopride. Neurogastroenterol Motil 1999;11:A256
87. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
88. Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil 2014;26(8):1079-86
89. Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther 2001;299(3):1007-12
90. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554(2-3):98-105
91. Boyce M, Kerstens R, Beyens G, et al. No Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebocontrolled, cross-over trials. Gastroenterology 2009;136:T1265
92. NHS Regional Drug and Therapeutics Centre (Newcastle). Cost Comparison Charts. 2014